Table 2 Overview of the demographic and clinical characteristics of participants in this study
|  | Healthy controls (n = 19) | PLWH (n = 25) | PLWH-CoV (n = 12) | p |
|---|---|---|---|---|
Age | 48 ± 10.19 | 50 ± 9.63 | 46.7 ± 10.76 | ns |
No. (%) males | 19 (100) | 25 (100) | 12 (100) | ns |
No. (%) of MSM | Â | 20 (80) | 10 (83.3) | ns |
No. (%) with viral loads < 50 copies/ml | 25 (100) | 12 (100) | ns | |
 CD4 count (cells/μl) |  | 539.72 ± 163.1 | 671.28 ± 243a | ns p = 0.13 |
 Nadir CD4 count (cells/μl) |  | 184.36 ± 123.1 | 154.2 ± 97.7 | ns |
 Time on ART (mo) |  | 105.92 ± 49.8 | 106 ± 44.5 | ns |
 BMI |  | 24.69 ± 3.6 | 27.5 ± 5.3 | ns p = 0.41 |
 No. (%) of SARS-CoV-2 vaccination | 0 | 0 | 2 (16.67) |  |
COVID-19 severity; No.(%) | ||||
 mild |  |  | 7 (58.3) |  |
 moderate |  |  | 4 (33.3) |  |
 severe |  |  | 1 (8.3) |  |
Medical history; No.(%) | ||||
 SARS-CoV-2 infection | 0 | 0 | 0 |  |
 AIDS | 0 | 5 (20) | 2 (16.67) | ns |
 diabetes | 0 | 0 | 1 (8.3) | ns |
 high blood pressure | 0 | 3 (12) | 2 (16.67) | ns |